Remeglurant

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 20:28, 2 April 2016 (Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Remeglurant
Clinical data
ATC code
  • None
Identifiers
  • (6-Bromopyrazolo[1,5-a]pyrimidin-2-yl)[(1R)-1-methyl-3,4-dihydro-2(1H)-isoquinolinyl]methanone
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC17H15BrN4O
Molar mass371.231 g/mol g·mol−1
3D model (JSmol)
  • C[C@@H]1c2ccccc2CCN1C(=O)c3cc4ncc(cn4n3)Br
  • InChI=1S/C17H15BrN4O/c1-11-14-5-3-2-4-12(14)6-7-21(11)17(23)15-8-16-19-9-13(18)10-22(16)20-15/h2-5,8-11H,6-7H2,1H3/t11-/m1/s1
  • Key:TUYZYSNXXSTKQX-LLVKDONJSA-N

Remeglurant (INN) is a drug which acts as a selective antagonist of the mGlu5 receptor.[1][2]

See also

References

  1. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2). World Health Organization.
  2. ^ Danysz W, et al. Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators. US Patent 7985753, 4 August 2006.